Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

• Status: Completed
• Trial end date: 2020-02-26
• Target enrollment: 0
• Participant gender: All

Summary

Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modality for Fibromyalgia is limited, however small trials have demonstrated its efficacy. No head to head comparisons between escitalopram and duloxetine have been undertaken. We aim to conduct a single blind, randomized control trial to assess the comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly diagnosed Fibromyalgia.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University
• Treatments: Citalopram; Dexetimide; Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Drug Naive patients

• Newly diagnosed with FIbromyalgia according to Modified ACR 2016 criteria

Exclusion Criteria:

• Concomitant depression/bipolar disorder or any other documented psychiatric illness

• Autoimmune disorders (SLE, RA)

• Peripheral Neuropathic pain due to any cause

• Uncontrolled hypertension

• Impaired renal or hepatic functions (on Lab assay)

• Chronic infections (e.g.Tuberculosis)